NEUP

Business Context and Reporting Period

Company: Neuphoria Therapeutics Inc. (formerly Bionomics Limited)

Filing Type: Form 10-K (Annual Report)

Reporting Period: Fiscal year ended June 30, 2025

Corporate Status: The Company redomiciled from Australia to Delaware on December 23, 2024, becoming a U.S. domestic issuer. It is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders, primarily advancing its lead candidate BNC210 for Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: License revenue increased from $0 in 2024 to $15.6 million in 2025. This was driven primarily by a $15 million milestone payment received from Merck & Co., Inc. in March 2025, triggered by the initiation of a Phase 2 clinical trial for MK-1167 (Alzheimer's disease). A smaller milestone payment of A$1 million was received from Carina Biotech in October 2024.
• Reduced Net Loss: The net loss narrowed significantly from $15.5 million in 2024 to $0.4 million in 2025, largely due to the recognition of the Merck milestone revenue.
• Expense Reduction: Research and Development (R&D) expenses decreased by 4.4% ($0.4 million) and General and Administrative (G&A) expenses decreased by 8.3% ($0.7 million) compared to the prior year. The R&D decrease was attributed to lower expenditures on the PTSD ATTUNE program, partially offset by increased costs for the SAD PREVAIL program.
• Capital Structure: The Company completed its redomiciliation to the U.S. and converted its Australian ordinary shares and ADSs into U.S. common stock. It also raised approximately $2.1 million through its At-The-Market (ATM) facility during the fiscal year.

Guidance, Outlook, and Risks

Clinical Pipeline and Outlook

• BNC210 (SAD): The Phase 3 AFFIRM-1 trial for acute treatment of SAD is underway, with topline results expected in the fourth quarter of calendar 2025. A second Phase 3 trial (AFFIRM-2) is planned for the first half of 2026, contingent on AFFIRM-1 results and capital availability.
• BNC210 (PTSD): Following a positive Phase 2b ATTUNE trial, the Company received FDA guidance for a registrational program. A Phase 2b/3 SYMPHONY trial is planned for initiation in the first half of 2026, contingent on capital.
• Merck Collaboration: The Company remains eligible for up to $450 million in additional milestone payments and royalties from Merck for the development of cognitive dysfunction therapies.

Liquidity and Capital Resources

Management believes existing cash and cash equivalents ($14.2 million) are sufficient to fund operations through the second quarter of fiscal year 2027. The Company has an active ATM facility with H.C. Wainwright & Co., LLC, with an aggregate offering amount of up to $11.5 million.

Key Risks and Contingencies

• Capital Requirements: As a clinical-stage company with no approved products, Neuphoria requires substantial additional financing to complete Phase 3 trials and commercialize products. Failure to secure funding could force delays or termination of programs.
• Clinical Trial Outcomes: Success is not guaranteed. The Phase 2 PREVAIL trial for SAD previously missed its primary endpoint, though post-hoc analysis showed encouraging trends. Future Phase 3 results are critical.
• Regulatory Approval: The Company relies on FDA approvals for BNC210. Delays or denials would materially harm the business.
• Going Concern: While management currently sees no substantial doubt about the ability to continue as a going concern for the next 12 months, the Company has a history of significant operating losses and an accumulated deficit of $178.3 million.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $14.2 million cash balance to fund the planned Phase 3 trials (AFFIRM-1 and SYMPHONY) through Q2 FY2027 without immediate dilution.
• Merck Milestone Dependency: Assess the sustainability of revenue given that the 2025 profit improvement was driven almost entirely by a one-time $15 million milestone payment.
• Phase 3 Trial Design: Review the specific endpoints and statistical power of the AFFIRM-1 (SAD) and SYMPHONY (PTSD) trials, particularly in light of the Phase 2 PREVAIL primary endpoint miss.
• ATM Facility Utilization: Monitor the pace of share sales under the $11.5 million ATM facility and the potential for shareholder dilution.
• Redomiciliation Impact: Confirm the tax implications and operational integration following the December 2024 redomiciliation from Australia to Delaware.